While canakinumab or IFN-γ inhibitors could be used to target specifically subjects at risk of obstructive CAD, therapeutics targeting IL-23/IL-17, developed to treat psoriasis, could be used to prevent specifically non-obstructive CAD [52]. Here, IL17A is linked to psoriasis.